Schizophrenia Relapse Screener Psychometrics


Enrollment: ONGOING


Study Purpose – Preventing Relapse in Schizophrenia


Health Analytics is currently testing their previously developed panel of relapse screeners. The screeners, intended to identify schizophrenia patients at an increased risk of relapse to allow proactive treatment intervention, are intended for regular use by patients, their providers, and patient collaterals. Ideally the screeners will allow patients to receive help early in the relapse process, resulting in better patient outcomes and quality of life. The goal of this study is to test the validity and reliability of the surveys, as well as reduce the number of survey questions to result in a short but predictive screener.


Study Design – 12 Month Longitudinal Study


At this time Health Analytics is working to validate the surveys with the assistance of 200 patients at multiple study sites across the country. The study includes three survey administrations over a period of 9 months followed by a study terminal chart review. Each patient survey administration takes approximately 1 hour, and includes both the patient relapse screener and the Positive and Negative Syndrome Scale (PANSS) a validated instrument to assess patient status. There is also the opportunity for providers and patient collaterals to complete their respective relapse screeners related to the patient’s recent behavior and symptoms.


There is no intervention in patient medication or treatment regimen associated with this study. Financial compensation is available for all study participants.


Enrollment - ONGOING


Health Analytics is currently recruiting study sites for patient enrollment and survey administration. This study has been approved by the Chesapeake Institutional Review Board.


Study sites must meet the following requirements:

  • Ability to enroll patients into the study that meet the following requirements:

    • Diagnosis of schizophrenia (ICD-9 CM 295.xx)

    • Exclusion of individuals with a schizoaffective or schizotypal diagnosis without a concurrent schizophrenia diagnosis

    • Treatment with antipsychotic medication

    • Not currently in an acute psychotic state or hospitalized

    • Aged 18 years or older

  • Onsite location for survey administration

  • Minimal administrative support for patient scheduling

  • Access to patient charts at study terminal review period


Health Analytics staff will coordinate and administer all surveys at the study site and the project will not impact the day to day activities of site staff. Financial compensation is available to all participating sites.



If you are interested in participating as a study site please contact Health Analytics:

Lorraine Yarngo

Study Coordinator

P. (410) 997-3314 x 115

F. (410) 997-4545


9200 Rumsey Rd

Suite 215

Columbia, MD 21045


Back to Current Studies

© 2018 by Health Analytics, LLC    +1 (410) 997-3314